Anatomical-Clinical Base of Adenocarcinoma Pancreatic

Neoplasms Clinical Trial

— BACAP-2  

Official title:

Anatomical-Clinical Base of Adenocarcinoma Pancreatic

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06128343
• Other study ID #: RC31/21/0191
• Secondary ID: 2021-A01050-41
• Status: Recruiting
• Start date: November 16, 2023
• Est. completion date: February 28, 2035

Study information

• Verified date: November 2023
• Source: University Hospital, Toulouse
• Contact: Barbara BOURNET, MD, PhD
• Phone: (0)5 61 32 32 35
• Email: bournet.b[@]chu-toulouse.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

BACAP-2 is a prospective biobank dedicated to the pancreatic adenocarcinoma including clinical data and biological samples from tumor. The aim is to enrich the previous propective collection BACAP in order to support future research projects.

Description:

Pancreatic cancer represents the fourth cause of death by cancer in Western countries. In over 90% of cases, it is due to an adenocarcinoma. The only curative treatment for pancreatic cancer remains the surgical exeresis. This one can only be suggested as a curative treatment in only 10 to 15% of cases. Besides, prevention or screening is difficult to set up due to the absence of clearly identified risk factors or groups and to the absence of useful markers for the diagnosis in clinical practice. The research efforts in this area must face a double challenge: saving time while improving the diagnosis period and strengthen the therapeutic equipment. It is important to identify and characterise the new molecular markers applicable for a better diagnosis and/or treatment (especially the response factors to chemotherapy). The present project aims to enrich with fresh tumor tissue and somatic genetic analysis the existing propective collection BACAP in order to support support future research projects on: - the development of new diagnostic tools, - understanding the development of tumors of the pancreas - the development of new therapeutic targets - understanding the response to chemotherapy…

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 1500
• Est. completion date: February 28, 2035
• Est. primary completion date: January 31, 2035
• Gender: All
• Age group: 18 Years to 120 Years

Eligibility

Inclusion Criteria:

• Patient with pancreatic mass syndrome explored by ultrasound endoscopy with cytopuncture or
• Patient with pancreatic mass syndrome explored by an abdominal scanner with and without injection of product contrast and/or puncture of the mass or secondary lesions by radiological route or
• Patient with pancreatic adenocarcinoma proven histologically and/or cytologically

Exclusion Criteria:

• Patient with a pancreatic tumor whose analysis histological is not an adenocarcinoma
• Pregnant or breastfeeding patient

Related Conditions & MeSH terms

• Adenocarcinoma
• Carcinoma
• Neoplasms

Intervention

Other:
• collection of biological samples
Collection of biological samples including whole blood and micro-biopsy from tissue of pancreas

Locations

Country	Name	City	State
France	Béthune hospital center	Béthune
France	Haut-Lévêque Hospital	Bordeaux
France	Huriez Hospital	Lille
France	Jean Mermoz private hosptila	Lyon
France	Regional Cancer Center From Montpellier	Montpellier
France	Saint Eloi Hospital	Montpellier
France	PAU hospital	Pau
France	Rangueil hospital	Toulouse

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Toulouse

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Enrichment of prospective BACAP collection	This collection is coming to enrich the prospective BACAP collection of fresh tumor tissue and/or fixed from the micro-biopsy under endoscopic ultrasound	5 years